Search

Your search keyword '"Westerhout, Cynthia M."' showing total 56 results

Search Constraints

Start Over You searched for: Author "Westerhout, Cynthia M." Remove constraint Author: "Westerhout, Cynthia M." Database Academic Search Index Remove constraint Database: Academic Search Index
56 results on '"Westerhout, Cynthia M."'

Search Results

1. The empirical estimate of the survival and variance using a weighted composite endpoint.

2. Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study.

3. Composite End Points in Clinical Research: A Time for Reappraisal.

4. NT-PROBNP DURING SCREENING IN THE STUDY OF VERICIGUAT IN PARTICIPANTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL: INSIGHTS INTO OUTCOMES AND VERICIGUAT.

5. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.

6. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged.

7. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups.

8. Short- and Long-Term Risk Stratification in Acute Coronary Syndromes: The Added Value of Quantitative ST-Segment Depression and Multiple Biomarkers

9. The Power of More Than One.

10. Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial.

11. Computing the polytomous discrimination index.

12. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.

13. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.

14. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.

16. Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.

17. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.

18. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.

19. Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy.

20. ASSOCIATION OF HUB AND SPOKE PRACTICE PATTERNS WITH CORONARY INTERVENTION AND OUTCOMES IN NON ST ELEVATION ACUTE CORONARY SYNDROMES (NSTE ACS): INSIGHTS FROM THE EARLY GLYCOPROTEIN IIB/IIIA INHIBITION IN NSTE ACS (EARLY-ACS) TRIAL

23. The authors' reply:.

25. 1042-78 Does chronic infection with chlamydia pneumoniae influence the prognosis of acute coronary syndromes? insights from a nested matched case-control substudy of the GUSTO IV acute coronary syndromes trial.

26. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.

27. The association between meteorological events and acute heart failure: New insights from ASCEND-HF.

28. Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early After Myocardial Infarction [STREAM] Study).

29. The relationship between meteorological conditions and index acute coronary events in a global clinical trial.

30. Relative Prognostic Value of Baseline Q Wave and Time from Symptom Onset Among Men and Women With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

31. Usefulness of the QRS Score as a Strong Prognostic Marker in Patients Discharged After Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

32. Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention

33. Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes.

34. Effects of Socioeconomic Status on Mortality after Acute Myocardial Infarction

35. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.

36. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery

37. Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).

38. Impact of Sex on Long-term Mortality From Acute Myocardial Infarction vs Unstable Angina.

40. Hospital variation in treatment and outcomes in acute coronary syndromes: Insights from the Alberta Contemporary Acute Coronary Syndrome Patients Invasive Treatment Strategies (COAPT) study.

41. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

42. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction.

43. Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis.

44. Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF.

45. Dietary fatty acids intake and mortality in patients with heart failure.

46. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial.

48. EJECTION FRACTION, BIOMARKERS, AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION AND THE IMPACT OF VERICIGUAT ON OUTCOMES IN THE VICTORIA TRIAL.

50. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.

Catalog

Books, media, physical & digital resources